中国医院用药评价与分析Issue(7)：602-605,4.
埃克替尼与吉非替尼治疗既往化疗失败的局部晚期或转移性非小细胞肺癌患者的系统性评价
Efficacy and Safety of Icotinib and Gefitinib for Localized Advanced or Metastatic Non-small-cell Lung Carcinoma after Treatment Failure with Chemotherapy:a Systematic Analysis
宋俞 1方罗 1戚雅君1
作者信息
- 1. 浙江省肿瘤医院药剂科，杭州 310022
- 折叠
摘要
Abstract
OBJECTIVE:To evaluate the short-term efficacy and safety of icotinib versus gefitinib for localized advanced or metastatic non-small-cell lung carcinoma (NSCLC). METHODS:The randomized controlled trials (RCTs) both at home and abroad on icotinib versus gefitinib for treatment of localized advanced or metastatic NSCLC after treatment failure with chemothera-py were retrieved from such databases as Medline,Embase,Cochrane Library,CBM,CNKI,CMCC and Wanfang database. Liter-ature screening,assessment and analysis were carried out. Meta-analysis on the short-term efficacy and safety of the drugs were per-formed using RevMan 4.2. RESULTS:Two RCTs involving 423 patients meeting our inclusion criteria were included. The Me-ta-analysis revealed satisfactory homogeneity test results which can be analyzed using fixed effect model and no significant differenc-es between gefitinib and icotinib in disease control rate of 4 weeks,half year survival rate and 1-year survival rate. However,the icotinib group showed better disease control rate of 28 weeks than did gefitinib group. No significant differences were noted be-tween gefitinib group and icotinib group in the incidences of rash,diarrhea and hemoptysis;however,the total incidence rate of ad-verse drug reactions in icotinib group was statistically lower than in the gefitinib group (P<0.000 01). CONCLUSIONS:For pa-tients with advanced NSCLC,icotinib is similar to gefitinib in efficacy and has better tolerance than gefitinib.关键词
埃克替尼/吉非替尼/非小细胞肺癌/Meta分析Key words
Icotinib/Gefitinib/NSCLC/Meta-analysis分类
医药卫生引用本文复制引用
宋俞,方罗,戚雅君..埃克替尼与吉非替尼治疗既往化疗失败的局部晚期或转移性非小细胞肺癌患者的系统性评价[J].中国医院用药评价与分析,2014,(7):602-605,4.
